Coherus BioSciences Inc expected to post a loss of 13 cents a share - Earnings Preview

Coherus Oncology

07/03/2025 20:30

Coherus BioSciences Inc CHRS.OQ CHRS.O is expected to show a fall in quarterly revenue when it reports  results on March 10 for the period ending December 31 2024

The Redwood City California-based  company is expected to report a 48.4% decrease in revenue to $47.27 million from $91.52 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Coherus BioSciences Inc is for a loss of 13 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Coherus BioSciences Inc is $7.00​, above​ its last closing price of $1.00. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.16
-0.13
-0.01
Beat
92.5
Jun. 30 2024
-0.29
-0.29
-0.14
Beat
51.7
Mar. 31 2024
-0.25
-0.24
-0.32
Missed
-32.3​
Dec. 31 2023
-0.14
-0.12
-0.62
Missed
-420.3
​​Sep. 30 2023
-0.29
-0.27
-0.27
Met
1.7
Jun. 30 2023
-0.48
-0.48
-0.38
Beat
21.6​
Mar. 31 2023
-0.54
-0.57
-0.75
Missed
-31
Dec. 31 2022
-0.87
-0.84
-0.60
Beat
28.4

This summary was machine generated March 7 at 20:30 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)